Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting

Clinical Cancer Research

Volumn 21, Issue 6, 2015, Pages 1329-1339

  Beuselinck, Benoit ^a,b,c,e   Job, Sylvie ^f   Becht, Etienne ^b,c,d   Karadimou, Alexandra ^a,b,c   Verkarre, Virginie ^b,g   Couchy, Gabrielle ^a,b,c   Giraldo, Nicolas ^b,d   Rioux Leclercq, Nathalie ^h   Molinié, Vincent ⁱ   Sibony, Mathilde ^b,j   Elaidi, Reza ^e   Teghom, Corinne ^e   Patard, Jean Jacques ^k   Méjean, Arnaud ^b,e   Fridman, Wolf Herman ^b,c,d   Sautès Fridman, Catherine ^b,c,d   De Reyniès, Aurélien ^f   Oudard, Stéphane ^b,e   Zucman Rossi, Jessica ^a,b,c,e  

^a Université Paris 13   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Labex Immuno oncology   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f Cartes d'Identité des Tumeurs Program Ligue Nationale Contre le Cancer   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ Clinique St Joseph   (France)

^j Institut Cochin   (France)

^k BICÊTRE HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MOLECULAR MARKER; PROGRAMMED DEATH 1 RECEPTOR; SUNITINIB; TRANSCRIPTOME; VON HIPPEL LINDAU PROTEIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURGERY; CELLULAR IMMUNITY; CELLULAR STRESS RESPONSE; CHROMOSOME; COPY NUMBER VARIATION; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; DRUG SENSITIVITY; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPOXIA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MOLECULAR TYPING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PBRM1 GENE; PDCD 1 GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SARCOMATOID CARCINOMA; TH1 CELL; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR MICROENVIRONMENT; VON HIPPEL LINDAU GENE; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CLASSIFICATION; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; KIDNEY NEOPLASMS; MALE; MUTATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MUTATION; PYRROLES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84927592892     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1128     Document Type: Article

References (40)

1. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:3584-90.
3. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009;10:992-1000.
4. Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010;1:152-63.
5. Brannon AR, Haake SM, Hacker KE, Pruthi RS, Wallen EM, Nielsen ME, et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol 2012;61:258-68.
6. Cancer Genome Atlas Research N. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499:43-9.
7. Kapur P, Pena-Llopis S, Christie A, Zhrebker L, Pavia-Jimenez A, Rathmell WK, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013;14:159-67.
8. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013;45:860-7.
9. Klatte T, Kroeger N, Rampersaud EN, Birkhauser FD, Logan JE, Sonn G, et al. Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. Cancer 2012;118:5777-82.
10. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol 2011;24:1470-9.
11. La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 2010;116:4696-702.
12. Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009;27:746-53.
13. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008;180:860-5; discussion 5-6.
14. Popova T, Manie E, Stoppa-Lyonnet D, Rigaill G, Barillot E, Stern MH. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol 2009;10:R128.
15. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-12.
16. Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, et al. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat 2012;132:29-39.
17. Houseman EA, Christensen BC, Yeh RF, Marsit CJ, Karagas MR, Wrensch M, et al. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions. BMC Bioinformatics 2008;9:365.
18. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61.
19. Huang Y, Niu B, Gao Y, Fu L, Li W. CD-HIT Suite: a web server for clustering and comparing biological sequences. Bioinformatics 2010;26:680-2.
20. Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a data set via the gap statistic. J R Stat Soc Ser B Stat Methodol 2001;63:411-23.
21. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782-95.
22. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013;19:4079-91.
23. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9.
24. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
25. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma:memorial Sloan-Kettering cancer center experience. Clin Cancer Res 2004;10(18 Pt 2):6302S-3S.
26. Yao M, Yoshida M, Kishida T, Nakaigawa N, Baba M, Kobayashi K, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94:1569-75.
27. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008;123:395-400.
28. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009;27:235-41.
29. Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, et al. Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease. Am J Clin Oncol 2011;34:454-9.
30. Fujita T, Iwamura M, Ishii D, Tabata K, Matsumoto K, Yoshida K, et al. Creactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol 2012;19:908-13.
31. Beuselinck B, Vano YA, Oudard S, Wolter P, DeSmet R, Depoorter L, et al. Prognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma patients treated with sunitinib. BJU Int 2014;114:81-9.
32. Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 2013;3:49.
33. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82.
34. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, et al. A decrease of regulatory T cells correlates with overall survival after sunitinibbased antiangiogenic therapy inmetastatic renal cancer patients. J Immunother 2010;33:991-8.
35. Apostolou E, Hochedlinger K. Chromatin dynamics during cellular reprogramming. Nature 2013;502:462-71.
36. Hugonnet F, Fournier L, Medioni J, Smadja C, Hindie E, Huchet V, et al. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med 2011; 52:1048-55.
37. Iacovelli R, Lanoy E, Albiges L, Escudier B. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int 2012;110:1747-53.
38. Ricketts CJ, Morris MR, Gentle D, Shuib S, Brown M, Clarke N, et al. Methylation profiling and evaluation of demethylating therapy in renal cell carcinoma. Clin Epigenetics 2013;5:16.
39. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
40. Giraldo NA, Becht E, Remark R, Damotte D, Sautes-Fridman C, Fridman WH. The immune contexture of primary and metastatic human tumours. Curr Opin Immunol 2014;27C:8 -15.